Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. - Wikidata - wikimedia - TriplyDB

Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer.

Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer.

http://www.wikidata.org/entity/Q38175030

about

Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS Genotyping A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mut Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?Panitumumab for the treatment of metastatic colorectal cancer: a review.Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies.Inhibition of protein phosphatase 5 (PP5) suppresses survival and growth of colorectal cancer cells.A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models.Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer.

P2860

Q33649652-401F1092-BEA5-4B3C-9A90-0D0DA99C2738 Q35624250-4E45E253-1500-4A5E-A0A2-A3E18DEF7461 Q36148358-D99FDD94-C69A-48F0-BBCD-F20B1CD4B3E4 Q38214511-D5C0BD46-9DB5-410E-A6A1-F8640B8E9F24 Q38268569-B879843A-12C0-4179-92FE-9098D9CE14F5 Q38562067-A11E7F2A-CEE3-4B53-A730-1F3BBF0B80D6 Q38910834-0454EEC8-CEC7-4CBD-B5AE-AE8CA9FD97D6 Q38947186-0C2379E7-05A4-4ABB-BF00-1324B478DA94 Q47739279-0F45EE62-82A0-4263-BE4B-B0A6E54FC006 Q51075547-B3859BE5-8ED8-4FCB-9D47-07AF0B8881C6

P2860

Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer.

http://www.wikidata.org/entity/Q38175030

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Panitumumab in the management ...... metastatic colorectal cancer.

@en

type

label

Panitumumab in the management ...... metastatic colorectal cancer.

@en

prefLabel

Panitumumab in the management ...... metastatic colorectal cancer.

@en

P1433

Q38175030-28209110-688E-42C1-A497-951A66BAF38D

P1476

Q38175030-2AD81AEF-F9AA-484B-9521-9E65E40B19FC

P2093

Q38175030-296B69C6-B575-4E7B-8C92-B4A38F19B976

P2860

Q38175030-0127D7E3-0489-4DD0-B445-2E5753D4D1EA

Q38175030-01448BAB-56DA-469B-8A9A-EDDA1D8DB283

Q38175030-169B3CD3-23E3-4297-BA17-69080C7939DC

Q38175030-170FEF5E-8415-4C0D-8FB7-7F76BCD5FFC6

Q38175030-23C27F33-B384-4EFA-A953-6C52B94B0619

Q38175030-25CB1F64-BB6B-44B1-BA6C-A737B7421259

Q38175030-274B05F4-4ACE-4774-8623-54E7F0F52773

Q38175030-28D5AD91-C3C0-4136-BE7B-0C3479FE27BE

Q38175030-2D536E49-1302-498D-BFA4-C2B9EEA7C773

Q38175030-343B303E-07ED-4390-A5AB-4FA4AA7A252A

P304

Q38175030-608B98BB-68BC-4180-A699-04E143B359B1

P31

Q38175030-224D4132-D371-4C98-984D-CB989DF5F3A3

P356

Q38175030-1D4E0D43-CFF2-41BC-80BB-2FB5FD45A37E

P433

Q38175030-E75118B3-35FD-4C19-AE33-8EC9646F0B68

P478

Q38175030-31BE1D8E-8C45-4990-83ED-08EBF8985618

P50

Q38175030-FC31081A-5EA2-452B-9CFA-4DD756E00A53

P577

Q38175030-0EFA4B0C-8C42-4101-8FD2-712092A5C904

P5875

Q38175030-A3D829F1-5780-4113-860A-7BAEEA67D86F

P698

Q38175030-D411C79E-E459-48BE-ACE9-63B1BDE28B03

P921

Q38175030-17392AA3-7621-489C-A49F-CEABCE655134

P932

Q38175030-A7F6DE0D-841C-43FB-921F-CE5A81C3183E

P356

1756283X13498660

P1433

Therapeutic Advances in Gastroenterology

P1476

Panitumumab in the management ...... e metastatic colorectal cancer

@en

P2093

Christopher M Hocking

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

P304

20-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756283X13498660

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259530640

http://www.w3.org/2001/XMLSchema#string

P698

24381645

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3871277

http://www.w3.org/2001/XMLSchema#string